Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS and Comparison with Other Ethnic Populations

about

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.

P2860

Q55190915-4085CA5D-A137-4AE2-A9D3-1B9BAA710250

P2860

Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS and Comparison with Other Ethnic Populations

Item

http://www.wikidata.org/entity/Q42234492

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pharmacokinetic Evaluation of ...... with Other Ethnic Populations

@en

Pharmacokinetic Evaluation of ...... with Other Ethnic Populations

@nl

type

Item

label

Pharmacokinetic Evaluation of ...... with Other Ethnic Populations

@en

Pharmacokinetic Evaluation of ...... with Other Ethnic Populations

@nl

prefLabel

Pharmacokinetic Evaluation of ...... with Other Ethnic Populations

@en

Pharmacokinetic Evaluation of ...... with Other Ethnic Populations

@nl

P1476

Pharmacokinetic Evaluation of ...... with Other Ethnic Populations

@en

P2093

Eman S Elzanfaly

http://www.w3.org/2001/XMLSchema#string

Mohamed M Elmazar

http://www.w3.org/2001/XMLSchema#string

Nermeen Ashoush

http://www.w3.org/2001/XMLSchema#string

Shereen Mowaka

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus.

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

Pharmacokinetics of a multicomponent herbal preparation in healthy Chinese and African volunteers.

A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats.

Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats.

Integrated identification, qualification and quantification strategy for pharmacokinetic profile study of Guizhi Fuling capsule in healthy volunteers.

Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes.

Pharmacokinetic comparison between quercetin and quercetin 3-O-β-glucuronide in rats by UHPLC-MS/MS.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.

Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor.

P2888

s41598-017-02895-7

P304

2583

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-02895-7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bassam M. Ayoub

Shaker A Mousa

P577

2017-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085634175

http://www.w3.org/2001/XMLSchema#string

P698

28566743

http://www.w3.org/2001/XMLSchema#string

P932

5451423

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS and Comparison with Other Ethnic Populations

about

P2860

P2860

Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS and Comparison with Other Ethnic Populations

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932